|
July 1, 2007
Cancer Management: A Multidisciplinary Approach, 10th Edition (2007).
Chapter 24
Bone sarcomas
Alan W. Yasko, MD, and Warren Chow, MD
Bone sarcomas are extremely rare neoplasms, which precludes determination of their true incidence. Approximately 2,760 new cases are identified annually in the United States. Population-based tumor registries seldom separate bone sarcomas into various histologic types. Osteosarcoma is the most common malignant primary bone tumor (excluding multiple myeloma), comprising 30% of all such malignancies. The annual incidence of osteosarcoma is approximately 800 cases per year in the United States. Chondrosarcoma is the second most common malignant primary tumor of bone; its annual incidence is approximately half that of osteosarcoma. Ewing’s sarcoma represents approximately 6% of all primary malignant bone tumors, with an annual incidence of 200 cases. Malignant fibrous histiocytoma (MFH) comprises < 1% of primary bone sarcomas.
EpidemiologyGender The incidence of primary bone sarcomas is higher in males than in females regardless of histologic type. A low-grade variant of osteosarcoma (parosteal osteosarcoma) is observed more frequently in females. Etiology and risk factorsFor the majority of bone sarcomas, no specific etiology has been established. A few predisposing factors have been identified. Signs and symptomsLocal symptoms Localized pain and swelling are the hallmark clinical features of bone sarcomas. The pain, which initially is insidious and transient, becomes progressively more severe and unremitting. Localized soft-tissue swelling, with or without associated warmth and erythema, may be present. A joint effusion may be observed, and range of motion of the adjacent joint may be limited and painful. Movement or weight-bearing of the involved extremity may exacerbate local symptoms.
Table of Contents
Chapter 1: Principles of Surgical Oncology
Chapter 2: Principles of Radiation Therapy Chapter 3: Principles of Oncologic Pharmacotherapy Chapter 4: Head and Neck Tumors Chapter 5: Thyroid and Parathyroid Cancers Chapter 6: Non–Small-Cell Lung Cancer Chapter 7: SCLC, Mesothelioma, Thymoma Chapter 8: Breast Cancer Overview Chapter 9: Stages 0 and I Breast Cancer Chapter 10: Stage II Breast Cancer Chapter 11: Stage III Breast Cancer Chapter 12: Esophageal Cancer Chapter 13: Gastric Cancer Chapter 14: Pancreatic, Neuroendocrine GI, and Adrenal Cancers Chapter 15: Liver, Gall Bladder, and Biliary Tract Cancer Chapter 16: Colon, Rectal, and Anal Cancers Chapter 17: Prostate Cancer Chapter 18: Testicular Cancer Chapter 19: Urothelial and Kidney Cancers Chapter 20: Cervical Cancer Chapter 21: Uterine Corpus Tumors Chapter 22: Ovarian Cancer Chapter 23: Melanoma and Other Skin Cancers Chapter 24: Bone Sarcomas Chapter 25: Soft-tissue Sarcomas Chapter 26: Primary and Metastatic Brain Tumors Chapter 27: AIDS-related Malignancies Chapter 28: Carcinoma of an Unknown Primary Site Chapter 29: Hodgkin's Lymphoma Chapter 30: Non-Hodgkin's Lymphoma Chapter 31: Multiple Myeloma and Other Plasma Cell Dyscrasias Chapter 32: Acute Leukemias Chapter 33: Chronic Myelogenous Leukemia Chapter 34: Chronic Lymphocytic Leukemia Chapter 35: Myelodysplastic Syndromes Chapter 36: Hematopoietic Cell Transplantation Chapter 37: Pain Management Chapter 38: Management of Nausea and Vomiting Chapter 39: Depression, Anxiety, and Delirium Chapter 40: Hematopoietic Growth Factors Chapter 41: Fatigue and Dyspnea Chapter 42: Anorexia and Cachexia Chapter 43: Long-term Venous Access Chapter 44: Prevention and Management of Radiation Toxicity Chapter 45: Oncologic Emergencies Chapter 46: Infectious Complications Chapter 47: Fluid Complications Appendix 1: Performance Scales Appendix 2: Cancer Info on the Internet Appendix 3: Cancer Drugs and Indications Appendix 4: Chemotherapeutic Agents and Their Uses, Dosages, and Toxicites |
|